GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (OTCPK:NONOF) » Definitions » Debt-to-Revenue

NONOF (Novo Nordisk AS) Debt-to-Revenue : 0.30 (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Novo Nordisk AS Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Novo Nordisk AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $1,841 Mil. Novo Nordisk AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $12,591 Mil. Novo Nordisk AS's annualized Revenue for the quarter that ended in Dec. 2024 was $48,122 Mil. Novo Nordisk AS's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.30.


Novo Nordisk AS Debt-to-Revenue Historical Data

The historical data trend for Novo Nordisk AS's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Debt-to-Revenue Chart

Novo Nordisk AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.19 0.15 0.12 0.35

Novo Nordisk AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.10 0.21 0.20 0.30

Competitive Comparison of Novo Nordisk AS's Debt-to-Revenue

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Debt-to-Revenue falls into.



Novo Nordisk AS Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Novo Nordisk AS's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1841.17 + 12590.949) / 40774.912
=0.35

Novo Nordisk AS's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1841.17 + 12590.949) / 48122.324
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Novo Nordisk AS Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.